YILDIRIM, H. Ç. Et Al. 2024. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study. JOURNAL OF CHEMOTHERAPY .

YILDIRIM, H. Ç., Kapar, C., KÖKSAL, B., Seyyar, M., CAN ŞANCI, P., GULIYEV, M., ... Perkin, P.(2024). Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study. JOURNAL OF CHEMOTHERAPY .

YILDIRIM, HASAN Et Al. "Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study," JOURNAL OF CHEMOTHERAPY , 2024

YILDIRIM, HASAN Ç. Et Al. "Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study." JOURNAL OF CHEMOTHERAPY , 2024

YILDIRIM, H. Ç. Et Al. (2024) . "Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study." JOURNAL OF CHEMOTHERAPY .

@article{article, author={HASAN ÇAĞRI YILDIRIM Et Al. }, title={Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study}, journal={JOURNAL OF CHEMOTHERAPY}, year=2024}